CC Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Chemours Company (CC) is currently showing signs of potential oversold conditions based on technical indicators. The Relative Strength Index (RSI) is at 31.80, indicating that the stock may be undervalued and due for a rebound. The MACD is currently negative (-1.18), suggesting bearish momentum, but the MACD histogram is showing early signs of a potential reversal.
News and Sentiment Analysis:
Recent news indicates mixed sentiment among analysts. Barclays maintained a Hold rating with a price target of $19.00, while Truist Financial issued a Buy rating. The stock is approaching its ex-dividend date, which may cause a short-term price adjustment, but the overall sentiment remains cautiously optimistic.
Fibonacci Levels:
The Fibonacci levels suggest that the stock is currently testing a critical support level. The pivot point is at $14.93, with resistance levels at $16.25 and $17.06. The stock is currently trading near the lower end of its Fibonacci range, which may indicate a potential bounce.
Conclusion:
Based on the oversold RSI, mixed analyst sentiment, and proximity to key Fibonacci support levels, the stock is likely to experience a short-term rebound. The target price for the next trading week is $15.50, and the recommendation is to buy at current levels with a stop-loss below $13.50.
CC Similar Chart Price Prediction
The price of CC is predicted to go up -48.37%, based on the high correlation periods with CAL. The similarity of these two price pattern on the periods is 98.74%.
CC
CAL
Down: -48.37%Similarity: 98.74%
CC Revenue Forecast
CC EPS Forecast
CC FAQs
What is CC revenue forecast for next quarter？
What is CC eps forecast for next quarter？
CC Analyst's Forecast
Michael Leithead
Barclays
Hold
2025-02-24
Price Target
$23 → $19
Upside
+17.61%
Barclays lowered the firm's price target on Chemours to $19 from $23 and keeps an Equal Weight rating on the shares. The firm thinks new management is executing well to "better re-position and stabilize" Chemours after a volatile 2024. However, difficult end markets and the company's leverage continue to make the recovery pathway less clear, the analyst tells investors in a research note.
John Roberts
Mizuho
Hold
2025-01-07
Price Target
$22 → $21
Upside
+11.88%
Michael Leithead
Barclays
Hold
2024-11-05
Price Target
$21 → $23
Upside
+14.37%
